Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRAT: Monalizumab After Allogeneic Stem Cell Transplantation
NCT02921685Phase 1Unknown
- Sponsor
- Institut Paoli-Calmettes
- Start
- Nov 2016
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of monalizumab in hematologic malignancy, sponsored by Institut Paoli-Calmettes. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
monalizumab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02921685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921685.